针对decapenylphosphoryl-β-D-ribose 2'-epimerase,用于开发针对Mycobacterium Tuberculosis耐药菌株的创新药物
Ghyzlane El Haddoumi1, Mariam Mansouri1, Jouhaina Kourou1
1Biotechnology Lab (MedBiotech), Bioinova Research Center, Rabat Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco.
Bioinformatics and biology insights
|May 30, 2024
概括
这项研究确定了针对DprE1酶的新型候选药物,以对抗耐药结核病. 干2显示出前景,特别是针对DprE1突变,增强药物开发策略.
科学领域:
- 药物的发现和开发.
- 计算化学是一种计算化学.
- 分子生物学分子生物学
背景情况:
- 结核病 (TB) 构成全球健康威胁,原因是新出现的耐药性结核菌菌菌株.
- 脱烯-β-D-利酶2'-表皮酶 (DprE1) 酶是新型抗结核药物的关键标,因为它在细胞壁合成和毒性中的作用.
研究的目的:
- 通过虚拟查来识别针对DprE1酶的潜在候选药物.
- 通过分子动力学模拟,研究DprE1突变对蛋白质结构和药物相互作用的影响.
- 评估已识别的化合物的疗效,特别是对突变DprE1.1的利甘德2的疗效.
主要方法:
- 111个具有已知的DprE1抑制活性的蛋白质数据库 (PDB) 分子的虚拟选.
- 分子动态模拟来分析10个DprE1突变 (包括C387N) 对蛋白质行为的影响.
- 基于联体的药分析,以评估已识别的化合物,包括联体2,与DprE1及其突变的结合亲和力和相互作用.
主要成果:
- 包括PubChem ID 390820 (Ligand 2) 在内的六种化合物显示出有前途的DprE1抑制活性,并与临床试验抑制剂进行了验证.
- DprE1中的C387N突变显著改变了蛋白质结构,这是RMSD,RMSF,Rg和SASA分析所证明的.
- 灵干2与C387N突变的DprE1表现出增强的结合亲和力和稳定性,改善了结并减少了波动.
结论:
- 连接物2是治疗耐药结核病的有前途的候选药物,对突变DprE1.1具有有效性.
- 计算和药理学方法为药物向相互作用和蛋白质稳定性提供了宝贵的见解.
- 这项研究为开发针对耐药结核病的有针对性的干预措施提供了基础,强调了 Ligand 2 的潜力.
相关概念视频
01:28Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:26Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K